Author

I. Blanco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 2 Immunology· 2 Biophysics· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 6 Research Focus:host-pathogen & immune response· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

B. Clotet· 5 shared J. Blanco· 5 shared J. Carrillo· 5 shared J. Segales· 4 shared J. Vergara-Alert· 4 shared N. Izquierdo-Useros· 4 shared R. Paredes· 4 shared V. Guallar· 4 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

B. Clotet

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas

H. Mazuelas, M. Magallon-Lorenz, I. Uriarte-Arrazola, A. Negro, I. Rosas, I. Blanco, E. Castellanos, C. Lazaro, B. Gel Moreno, M. Carrio, E. Serra

This study identifies a therapeutic strategy for cutaneous neurofibromas by combining a MEKi and a cAMP elevator to disrupt SC-FB crosstalk and inhibit tumor growth.

JCI Insight · Feb 8, 2024Peer-reviewedCancer Biology

MERLIN-DEFICIENT iPSCs AS AN IN VITRO MODEL SYSTEM FOR STUDIYNG NF2 PATHOGENESIS

N. Catasus, M. Torres-Martin, A. Negro, B. Kuebler, I. Rosas, G. Casals, H. Mazuelas, F. Roca-Ribas, E. Amilibia, B. Aran, A. Veiga, A. Raya, B. Gel Moreno, I. Blanco, E. Serra, , E. CASTELLANOS

The paper generates and characterizes NF2-deficient iPSCs to study NF2 pathogenesis, showing they can model merlin-deficient Schwann cell features in vitro.

bioRxiv · Dec 14, 2022 · PreprintCell Biology

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

F. Tarres-Freixas, B. Trinite, A. Pons-Grifols, M. Romero-Durana, E. Riveira-Munoz, C. Avila-Nieto, M. Perez, E. Garcia-Vidal, D. Perez-Zsolt, J. Munoz-Basagoiti, D. Raich-Regue, N. Izquierdo-Useros, I. Blanco, M. Noguera-Julian, V. Guallar, , J. Blanco

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

bioRxiv · Aug 3, 2021 · PreprintMicrobiology

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

D. Perez-Zsolt, J. Munoz Basagoiti, J. Rodo, M. Elousa, D. Raich Regue, C. Risco, M. Sachse, M. Pino, S. Gumber, M. Paiardini, J. Chojnacki, I. Erkizia, X. Muniz, E. Ballana, E. Riveira Munoz, , N. Izquierdo-Useros

This study shows Siglec-1 on APCs mediates SARS-CoV-2 trans-infection and triggers proinflammatory responses, suggesting it as a potential therapeutic target.

bioRxiv · May 11, 2021 · PreprintMicrobiology

Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection

A. Kilpelainen, E. Jimenez-Moyano, O. Blanch-Lombarte, D. Ouchi, R. Penya, B. Quirant-Sanchez, A. Chamorro, I. Blanco, E. Martinez-Caceres, R. Paredes, L. Mateu, J. Carrillo, J. Blanco, C. Brander, M. Massanella, , J. G Prado

The paper examines T-cell immunity in SARS-CoV-2 non-seroconvertors, finding high functional T-cell responses and low immune activation correlate with protection from severe disease without seroconversion.

bioRxiv · May 4, 2021 · PreprintImmunology

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

B. Trinite, E. Pradenas, S. Marfil, C. Rovirosa, V. Urrea, F. Tarres-Freixas, R. Ortiz, J. Vergara-Alert, J. Segales, V. Guallar, A. Lepore, N. Izquierdo-Useros, G. Trujillo, J. Trape, C. Gonzalez-Fernandez, , J. Blanco

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

bioRxiv · Mar 5, 2021Immunology

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

J. Rodon, J. Munoz-Basagoiti, D. Perez-Zsolt, M. Noguera-Julian, R. Paredes, L. Mateu, C. Quinones, I. Erkizia, I. Blanco, A. Valencia, V. Guallar, J. Carrillo, J. Blanco, J. Segales, B. Clotet, , N. Izquierdo-Useros

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.

bioRxiv · Apr 23, 2020 · PreprintMicrobiology

HUMAN PANCREATIC CANCER CELLS UNDERGO PROFOUND METABOLIC REPROGRAMMING TOWARDS CELLULAR STEMNESS AS ADAPTATION TO INHIBITION OF THE AKT PATHWAY

H. Arasanz, C. Hernandez, A. Bocanegra, L. Chocarro, M. Zuazo, M. Gato, K. Ausin, E. Santamaria, J. Fernandez, G. Fernandez, E. Monasterio, C. Rodriguez, I. Blanco, R. Vera, D. Escors, G. Kochan

This study shows that pancreatic cancer cells adapt to AKT pathway inhibition by reprogramming metabolism and acquiring stemness traits, which can be targeted with combined therapy.

bioRxiv · Apr 1, 2020 · PreprintCancer Biology

HCN domain is required for HCN channel expression and couples voltage- and cAMP-dependent gating mechanisms

Z.-J. Wang, I. Blanco, S. Hayoz, T. I. Brelidze

This study identifies the HCN domain as essential for HCN channel surface expression and reveals its role in coupling voltage- and cAMP-dependent gating mechanisms.

bioRxiv · Mar 2, 2020Biophysics